Global Cancer Generics Market Forecast to 2022
Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.
As per RNCOS report “Global Cancer Generics Market Forecast to 2022”, the global cancer generics market is anticipated to witness a double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global cancer generics market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global cancer generics market.
The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.
Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.
Based on geography, the report divides market into North America, Europe, and Asia-Pacific. In 2016, North America is estimated to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global generics industry.
The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.
As per RNCOS report “Global Cancer Generics Market Forecast to 2022”, the global cancer generics market is anticipated to witness a double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global cancer generics market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global cancer generics market.
The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.
Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.
Based on geography, the report divides market into North America, Europe, and Asia-Pacific. In 2016, North America is estimated to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global generics industry.
The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL CANCER DRUGS MARKET OUTLOOK 2022
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. MARKET DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Strategic Collaborations
4.1.3 Growing Geriatric Population
4.1.4 Ability to Curb Healthcare Cost
4.2 Challenges
4.2.1 Growing Backlog of Generic Drug Applications
4.2.2 Counterfeit Generic Drugs
4.3 Opportunities
4.3.1 Patent Expiry of Blockbuster Oncology Drugs
4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries
5. GLOBAL CANCER GENERICS MARKET ANALYSIS 2022
6. GLOBAL CANCER GENERICS MARKET BY MODE OF ADMINISTRATION
6.1 Oral Generics
6.1.1 Arimidex (Anastrozole)
6.1.2 Femara (Letrozole)
6.1.3 Hycamtin (Topotecan)
6.1.4 Stivarga (Regorafenib)
6.1.5 Tarceva (Erlotinib)
6.1.6 Xalkori (Crizotinib)
6.1.7 Xeloda (Capecitabine)
6.1.8 Gleevec/Glivec (Imatinib Mesylate)
6.1.9 Nolvadex (Tamoxifen Citrate)
6.1.10 Targretin (Bexarotene)
6.2 Injectables Generics
6.2.1 Camptosar (Irinotecan Hydrochloride)
6.2.2 Eloxatin (Oxaliplatin)
6.2.3 Gemzar (Gemcitabine Hydrochloride)
6.2.4 Navelbine (Vinorelbine Tartrate)
6.2.5 Platinol (Cisplatin)
6.2.6 Taxol (Paclitaxel)
6.2.7 Taxotere (Docetaxel)
6.2.8 Fusilev (Levoleucovorin)
6.2.9 Ellence (Epirubicin Hydrochloride)
6.2.10 Adriamycin (Doxorubicin Hydrochloride)
7. GLOBAL CANCER GENERICS MARKET BY MAJOR INDICATIONS
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Stomach Cancer
7.5 Prostate Cancer
8. GLOBAL CANCER GENERICS MARKET BY GEOGRAPHIC REGIONS
8.1 US
8.2 Europe
8.3 Asia-Pacific
9. TRENDS & DEVELOPMENTS
9.1 Generic Version of Blockbuster Cancer Drug
9.2 Entry of Indian Generic Cancer Drug in US
10. MERGERS & ACQUISITIONS
11. KEY PLAYERS
11.1 Fresenius Kabi AG
11.2 Pfizer Inc
11.3 Teva Pharmaceutical Industries Ltd
11.4 Mylan N.V
11.5 Sun Pharmaceutical Industries Ltd
11.6 Sandoz International GmbH - A Novartis Company
11.7 Sanofi
11.8 Dr. Reddy's Laboratories Ltd
11.9 Cipla Ltd
11.10 Apotex Inc
2. RESEARCH METHODOLOGY
3. GLOBAL CANCER DRUGS MARKET OUTLOOK 2022
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. MARKET DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Strategic Collaborations
4.1.3 Growing Geriatric Population
4.1.4 Ability to Curb Healthcare Cost
4.2 Challenges
4.2.1 Growing Backlog of Generic Drug Applications
4.2.2 Counterfeit Generic Drugs
4.3 Opportunities
4.3.1 Patent Expiry of Blockbuster Oncology Drugs
4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries
5. GLOBAL CANCER GENERICS MARKET ANALYSIS 2022
6. GLOBAL CANCER GENERICS MARKET BY MODE OF ADMINISTRATION
6.1 Oral Generics
6.1.1 Arimidex (Anastrozole)
6.1.2 Femara (Letrozole)
6.1.3 Hycamtin (Topotecan)
6.1.4 Stivarga (Regorafenib)
6.1.5 Tarceva (Erlotinib)
6.1.6 Xalkori (Crizotinib)
6.1.7 Xeloda (Capecitabine)
6.1.8 Gleevec/Glivec (Imatinib Mesylate)
6.1.9 Nolvadex (Tamoxifen Citrate)
6.1.10 Targretin (Bexarotene)
6.2 Injectables Generics
6.2.1 Camptosar (Irinotecan Hydrochloride)
6.2.2 Eloxatin (Oxaliplatin)
6.2.3 Gemzar (Gemcitabine Hydrochloride)
6.2.4 Navelbine (Vinorelbine Tartrate)
6.2.5 Platinol (Cisplatin)
6.2.6 Taxol (Paclitaxel)
6.2.7 Taxotere (Docetaxel)
6.2.8 Fusilev (Levoleucovorin)
6.2.9 Ellence (Epirubicin Hydrochloride)
6.2.10 Adriamycin (Doxorubicin Hydrochloride)
7. GLOBAL CANCER GENERICS MARKET BY MAJOR INDICATIONS
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Stomach Cancer
7.5 Prostate Cancer
8. GLOBAL CANCER GENERICS MARKET BY GEOGRAPHIC REGIONS
8.1 US
8.2 Europe
8.3 Asia-Pacific
9. TRENDS & DEVELOPMENTS
9.1 Generic Version of Blockbuster Cancer Drug
9.2 Entry of Indian Generic Cancer Drug in US
10. MERGERS & ACQUISITIONS
11. KEY PLAYERS
11.1 Fresenius Kabi AG
11.2 Pfizer Inc
11.3 Teva Pharmaceutical Industries Ltd
11.4 Mylan N.V
11.5 Sun Pharmaceutical Industries Ltd
11.6 Sandoz International GmbH - A Novartis Company
11.7 Sanofi
11.8 Dr. Reddy's Laboratories Ltd
11.9 Cipla Ltd
11.10 Apotex Inc
LIST OF FIGURES:
Figure 3-1: Global - Cancer Incidences (Million), 2015 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2015
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2016 & 2022
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 6-1: Global - Cancer Generics Market by Mode of Administration (%), 2016
Figure 7-1: Global - Cancer Generics Market by Major Indications (%), 2016
Figure 7-2: Global - Lung Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-3: Global -Lung Cancer Incidences (Million), 2015 & 2025
Figure 7-4: Global - Breast Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-5: Global -Breast Cancer Incidences (Million), 2015 & 2025
Figure 7-6: Global - Colorectal Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-7: Global -Colorectal Cancer Incidences (Million), 2015 & 2025
Figure 7-8: Global - Stomach Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-9: Global -Stomach Cancer Incidences (Million), 2015 & 2025
Figure 7-10: Global - Prostate Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-11: Global -Prostate Cancer Incidences (Million), 2015 & 2025
Figure 8-1: Global - Cancer Generics Market by Geographic Regions (%), 2016
Figure 8-2: US - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-3: US - Cancer Incidences (Million), 2015 & 2025
Figure 8-4: Europe - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-5: Europe - Cancer Incidences (Million), 2015 & 2025
Figure 8-6: Asia-Pacific - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-7: Asia-Pacific - Cancer Incidences (Million), 2015 & 2025
Figure 11-1: Fresenius Kabi AG - Sales by Product Segment (%), 2015
Figure 11-2: Fresenius Kabi AG - Sales by Geographic Region (%), 2015
Figure 11-3: Pfizer Inc - Revenue by Business Segment (%), 2015
Figure 11-4: Pfizer Inc - Revenue by Geographic Region (%), 2015
Figure 11-5: Teva Pharmaceutical - Revenue by Business Segment (%), 2015
Figure 11-6: Teva Pharmaceutical - Revenue by Geographic Region (%), 2015
Figure 11-7: Mylan N.V. - Revenue by Business Segment (%), 2015
Figure 11-8: Mylan N.V. - Revenue by Geographic Region (%), 2015
Figure 11-9: Sun Pharmaceutical - Total Income by Business Segment (%), FY 2016
Figure 11-10: Sun Pharmaceutical - Total Income by Geographic Region (%), FY 2016
Figure 11-11: Sandoz International GmbH - Net Sales by Franchise (%), 2015
Figure 11-12: Sanofi - Sales by Business Segment (%), 2015
Figure 11-13: Sanofi - Sales by Geographic Region (%), 2015
Figure 11-14: Dr. Reddy's Laboratories - Revenue by Business Segment (%), FY 2016
Figure 11-15: Dr. Reddy's Laboratories - Revenue by Geographic Region (%), FY 2016
Figure 11-16: Cipla Ltd. - Revenue by Geographic Region (%), FY 2016
Figure 3-1: Global - Cancer Incidences (Million), 2015 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2015
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2016 & 2022
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 6-1: Global - Cancer Generics Market by Mode of Administration (%), 2016
Figure 7-1: Global - Cancer Generics Market by Major Indications (%), 2016
Figure 7-2: Global - Lung Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-3: Global -Lung Cancer Incidences (Million), 2015 & 2025
Figure 7-4: Global - Breast Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-5: Global -Breast Cancer Incidences (Million), 2015 & 2025
Figure 7-6: Global - Colorectal Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-7: Global -Colorectal Cancer Incidences (Million), 2015 & 2025
Figure 7-8: Global - Stomach Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-9: Global -Stomach Cancer Incidences (Million), 2015 & 2025
Figure 7-10: Global - Prostate Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-11: Global -Prostate Cancer Incidences (Million), 2015 & 2025
Figure 8-1: Global - Cancer Generics Market by Geographic Regions (%), 2016
Figure 8-2: US - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-3: US - Cancer Incidences (Million), 2015 & 2025
Figure 8-4: Europe - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-5: Europe - Cancer Incidences (Million), 2015 & 2025
Figure 8-6: Asia-Pacific - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-7: Asia-Pacific - Cancer Incidences (Million), 2015 & 2025
Figure 11-1: Fresenius Kabi AG - Sales by Product Segment (%), 2015
Figure 11-2: Fresenius Kabi AG - Sales by Geographic Region (%), 2015
Figure 11-3: Pfizer Inc - Revenue by Business Segment (%), 2015
Figure 11-4: Pfizer Inc - Revenue by Geographic Region (%), 2015
Figure 11-5: Teva Pharmaceutical - Revenue by Business Segment (%), 2015
Figure 11-6: Teva Pharmaceutical - Revenue by Geographic Region (%), 2015
Figure 11-7: Mylan N.V. - Revenue by Business Segment (%), 2015
Figure 11-8: Mylan N.V. - Revenue by Geographic Region (%), 2015
Figure 11-9: Sun Pharmaceutical - Total Income by Business Segment (%), FY 2016
Figure 11-10: Sun Pharmaceutical - Total Income by Geographic Region (%), FY 2016
Figure 11-11: Sandoz International GmbH - Net Sales by Franchise (%), 2015
Figure 11-12: Sanofi - Sales by Business Segment (%), 2015
Figure 11-13: Sanofi - Sales by Geographic Region (%), 2015
Figure 11-14: Dr. Reddy's Laboratories - Revenue by Business Segment (%), FY 2016
Figure 11-15: Dr. Reddy's Laboratories - Revenue by Geographic Region (%), FY 2016
Figure 11-16: Cipla Ltd. - Revenue by Geographic Region (%), FY 2016
LIST OF TABLES:
Table 3-1: Most Prevalent Types of Cancer, 2015
Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 6-1: List of Companies Dealing in Generic Arimidex
Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 6-3: List of Companies Dealing in Generic Femara
Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 6-5: List of Companies Dealing in Generic Hycamtin
Table 6-6: List of Companies Dealing in Generic Xeloda
Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 6-8: List of Companies Dealing in Generic Gleevec
Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate)
Table 6-10: List of Companies Dealing in Generic Nolvadex
Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 6-12: List of Companies Dealing in Generic Targretin
Table 6-13: List of Companies Dealing in Generic Camptosar
Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 6-16: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 6-17: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 6-18: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 6-19: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 6-20: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 6-21: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 6-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 6-23: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-24: List of Companies Dealing in Generic Fusilev (Levoleucovorin)
Table 6-25: List of Companies Dealing in Generic Ellence (Epirubicin Hydrochloride)
Table 6-26: List of Companies Dealing in Generic Adriamycin (Doxorubicin Hydrochloride)
Table 7-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 7-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 7-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 7-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 7-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 10-1: Global - Major M&A in the Generics Industry (2014-2016)
Table 11-1: Fresenius Kabi AG - Sales (Billion US$), 2013, 2014 & 2015
Table 11-2: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 11-3: Pfizer Inc - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-4: Pfizer Inc - Key Cancer Generic Products
Table 11-5: Teva Pharmaceutical - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-6: Teva Pharmaceutical - Key Cancer Generic Drugs
Table 11-7: Mylan N.V. - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-8: Mylan N.V. - Key Cancer Generic Drugs
Table 11-9: Sun Pharmaceutical - Total Income (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-10: Sun Pharmaceutical - Key Cancer Generic Drugs
Table 11-11: Sandoz International GmbH - Sales (Billion US$), 2013, 2014 & 2015
Table 11-12: Sandoz International GmbH - Key Cancer Generic Drugs
Table 11-13: Sanofi - Net Sales (Billion US$), 2013, 2014 & 2015
Table 11-14: Sanofi - Key Cancer Generic Drugs
Table 11-15: Dr. Reddy's Laboratories - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-16: Dr. Reddy's Laboratories - Key Cancer Generic Drugs
Table 11-17: Cipla Ltd. - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-18: Cipla Ltd. - Key Cancer Generic Drugs
Table 11-19: Apotex Inc. - Key Cancer Generic Drugs
Table 3-1: Most Prevalent Types of Cancer, 2015
Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 6-1: List of Companies Dealing in Generic Arimidex
Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 6-3: List of Companies Dealing in Generic Femara
Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 6-5: List of Companies Dealing in Generic Hycamtin
Table 6-6: List of Companies Dealing in Generic Xeloda
Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 6-8: List of Companies Dealing in Generic Gleevec
Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate)
Table 6-10: List of Companies Dealing in Generic Nolvadex
Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 6-12: List of Companies Dealing in Generic Targretin
Table 6-13: List of Companies Dealing in Generic Camptosar
Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 6-16: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 6-17: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 6-18: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 6-19: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 6-20: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 6-21: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 6-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 6-23: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-24: List of Companies Dealing in Generic Fusilev (Levoleucovorin)
Table 6-25: List of Companies Dealing in Generic Ellence (Epirubicin Hydrochloride)
Table 6-26: List of Companies Dealing in Generic Adriamycin (Doxorubicin Hydrochloride)
Table 7-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 7-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 7-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 7-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 7-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 10-1: Global - Major M&A in the Generics Industry (2014-2016)
Table 11-1: Fresenius Kabi AG - Sales (Billion US$), 2013, 2014 & 2015
Table 11-2: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 11-3: Pfizer Inc - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-4: Pfizer Inc - Key Cancer Generic Products
Table 11-5: Teva Pharmaceutical - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-6: Teva Pharmaceutical - Key Cancer Generic Drugs
Table 11-7: Mylan N.V. - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-8: Mylan N.V. - Key Cancer Generic Drugs
Table 11-9: Sun Pharmaceutical - Total Income (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-10: Sun Pharmaceutical - Key Cancer Generic Drugs
Table 11-11: Sandoz International GmbH - Sales (Billion US$), 2013, 2014 & 2015
Table 11-12: Sandoz International GmbH - Key Cancer Generic Drugs
Table 11-13: Sanofi - Net Sales (Billion US$), 2013, 2014 & 2015
Table 11-14: Sanofi - Key Cancer Generic Drugs
Table 11-15: Dr. Reddy's Laboratories - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-16: Dr. Reddy's Laboratories - Key Cancer Generic Drugs
Table 11-17: Cipla Ltd. - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-18: Cipla Ltd. - Key Cancer Generic Drugs
Table 11-19: Apotex Inc. - Key Cancer Generic Drugs
